Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement

ByNicholas Jacobus

April 9th 2026

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

ByNicholas Jacobus

April 9th 2026

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers

ByJoshua Wyatt

April 9th 2026

How Does the Complexity of Obesity Impact the Effectiveness of GLP-1s?

ByMike Hollan,Mark Bagnall

April 9th 2026

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

ByNicholas Jacobus

April 8th 2026

Under Federal Fire

Articles in this issue

Newsletter

Related Content

Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers

How Does the Complexity of Obesity Impact the Effectiveness of GLP-1s?

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

Trending on PharmExec

Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report

Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees

What Unexpected Costs do GLP-1 Patients Face?